<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXYBUTYNIN CHLORIDE- oxybutynin chloride syrup </strong><br>Morton Grove Pharmaceuticals, Inc.<br></p></div>
<h1>OXYBUTYNIN CHLORIDE <br> SYRUP, USP <br> 5 mg/5 mL</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Chemically, oxybutynin chloride is 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate hydrochloride. The molecular formula of oxybutynin chloride is C<span class="Sub">22</span>H<span class="Sub">31</span>NO<span class="Sub">3</span>•HCl. The structural formula appears below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17d61203-a462-4393-b261-72bf48d51942&amp;name=oxybutinin-01.jpg"></div>
<p>Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.96. It is readily soluble in water and acids, but relatively insoluble in alkalis.</p>
<p>Each 5 mL, for oral administration, contains 5 mg of oxybutynin chloride. In addition, the following inactive ingredients are present: Artificial raspberry flavor; citric acid, USP; D&amp;C Yellow No. 10; FD&amp;C Blue No. 1; glycerin, USP; liquid sugar; methylparaben, NF; propylene glycol, USP; sodium citrate, USP and sorbitol solution, USP.</p>
<p>Therapeutic Category: Antispasmodic, anticholinergic.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Oxybutynin chloride exerts direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).</p>
<p>Oxybutynin chloride relaxes bladder smooth muscle. In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin chloride increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. Oxybutynin chloride thus decreases urgency and the frequency of both <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinent</span> episodes and voluntary urination.</p>
<p>Oxybutynin chloride was well tolerated in patients administered the drug in controlled studies of 30 days duration and in uncontrolled studies in which some patients received the drug for 2 years. Pharmacokinetic information is not currently available.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Oxybutynin chloride syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex <span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">neurogenic bladder</span> (ie, urgency, frequency, urinary leakage, <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oxybutynin chloride is contraindicated in patients with untreated <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span> and in patients with untreated narrow anterior chamber angles since anticholinergic drugs may aggravate these conditions.</p>
<p>It is also contraindicated in partial or complete obstruction of the gastrointestinal tract, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, intestinal atony of the elderly or debilitated patient, <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> complicating <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. It is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> and in patients with unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Oxybutynin chloride is contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Oxybutynin chloride, when administered in the presence of a high environmental temperature, can cause <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy, or colostomy. In this instance treatment with oxybutynin chloride would be inappropriate and possibly harmful.</p>
<p>Oxybutynin chloride may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.</p>
<p>Alcohol or other sedative drugs may enhance the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> caused by oxybutynin chloride.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Oxybutynin chloride should be used with caution in the elderly and in all patients with <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Oxybutynin chloride may aggravate the symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>.</p>
<p>Administration of oxybutynin chloride to patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> may suppress intestinal motility to the point of producing a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and precipitate or aggravate toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>, a serious complication of the disease.</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A 24-month study in rats at dosages up to approximately 400 times the recommended human dosage showed no evidence of carcinogenicity.</p>
<p>Oxybutynin chloride showed no increase of mutagenic activity when tested in <span class="Italics">Schizosaccharomyces </span><span class="Italics">pompholiciformis, Saccharomyces </span><span class="Italics">cerevisiae</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>test systems. Reproduction studies in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.2.1"></a><p></p>
<h3>Teratogenic Effects-Pregnancy Category B</h3>
<p class="First">Reproduction studies in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility or harm to the animal fetus. The safety of oxybutynin chloride administered to women who are or who may become pregnant has not been established. Therefore, oxybutynin chloride should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.3"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when oxybutynin chloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of oxybutynin chloride administration have been demonstrated for pediatric patients 5 years of age and older (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>). However, as there is insufficient clinical data for pediatric patients under age 5, oxybutynin chloride is not recommended for this age group.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Following administration of oxybutynin chloride, the symptoms that can be associated with the use of other anticholinergic drugs may occur:</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span></p>
<p><span class="Bold">Dermatologic: </span>Decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">Gastrointestinal/Genitourinary: </span><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, decreased gastrointestinal motility, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, urinary hesitance and retention</p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p><span class="Bold">Ophthalmic: </span><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>, decreased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span></p>
<p><span class="Bold">Other: </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, suppression of lactation</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The symptoms of overdosage with oxybutynin chloride may be any of those seen with other anticholinergic agents. Symptoms may include signs of central nervous system excitation (eg, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or exaggerated response, treatment should be symptomatic and supportive. Maintain respiration and induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or perform gastric lavage (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is contraindicated in precomatose patients, convulsive or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic state</span>). Activated charcoal may be administered as well as a cathartic. Physostigmine may be considered to reverse symptoms of anticholinergic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> may be treated symptomatically with ice bags or other <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> applications and sponges.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The usual dose is one teaspoonful (5 mg/5 mL) syrup two to three times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) syrup four times a day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Children over 5 years of age</h2>
<p class="First">The usual dose is one teaspoonful (5 mg/5 mL) two times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) three times a day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Oxybutynin Chloride Syrup, USP 5 mg/5 mL is a light aqua, raspberry-flavored liquid supplied in 1 Pint (473 mL) bottles.</p>
<p>Pharmacist: Dispense in tight, light-resistant container as defined in the USP.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Store at controlled room temperature 15 °–30 °C (59 °–86 °F).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Product No.: 8092</p>
<p><span class="Bold">Manufactured By:<br>Morton Grove Pharmaceuticals, Inc.<br>Morton Grove, IL 60053</span></p>
<p>A50-8092-16<br>REV. 11-04</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label</h1>
<p class="First"><span class="Bold">MGP</span></p>
<p><span class="Bold">NDC 60432-092-16</span></p>
<p><span class="Bold">OXYBUTYNIN CHLORIDE<br>SYRUP, USP<br>5 mg/5 mL</span></p>
<p><span class="Bold">Each teaspoonful (5 mL) contains:</span><br>5 mg oxybutynin chloride</p>
<p>DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED<br>FOR YOUR PROTECTION" IS BROKEN OR MISSING.</p>
<p><span class="Bold">BULK CONTAINER —<br> NOT FOR HOUSEHOLD USE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NET: 1 Pint (473 mL)</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=17d61203-a462-4393-b261-72bf48d51942&amp;name=oxybutinin-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXYBUTYNIN CHLORIDE 		
					</strong><br><span class="contentTableReg">oxybutynin chloride syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60432-092</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Oxybutynin Chloride</strong> (Oxybutynin) </td>
<td class="formItem">Oxybutynin Chloride</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Trisodium Citrate Dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Anhydrous Citric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sucrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sorbitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Propylene Glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Yellow No. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE, GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60432-092-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074868</td>
<td class="formItem">02/12/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Morton Grove Pharmaceuticals, Inc.
							(801897505)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PCAS France</td>
<td class="formItem"></td>
<td class="formItem">396133998</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>da22ff0d-ab08-432a-8cf0-3cb9d0b251b9</div>
<div>Set id: 17d61203-a462-4393-b261-72bf48d51942</div>
<div>Version: 2</div>
<div>Effective Time: 20120124</div>
</div>
</div> <div class="DistributorName">Morton Grove Pharmaceuticals, Inc.</div></p>
</body></html>
